Abstract: Bivalent epidermal growth factor (EGF) fusion toxin including two EGF domains are provided. The described fusion toxin demonstrates increased binding and cytotoxicity when compared to a fusion toxin having a single EGF binding domain (monovalent). Methods for treating epidermal growth factor receptor (EGFR)-positive cancers and related materials are also provided.

Abstract: Embodiments disclosed herein relate to compositions and methods for inducing transplantation tolerance using immunomodulation agents. In certain embodiments compositions and methods disclosed herein, concern administering a composition including, but not limited to, anti-CD3 immunotoxin and administering a composition including, but not limited to, peripheral blood cells obtained from a donor of an organ, tissue or cells to be transplanted. In some embodiments, compositions and methods disclosed here can be used for modulating B- and/or T-cell-mediated immunity and/or rejection by reducing or eliminating anti-donor antibody production. Other embodiments concern modulating T-cell production in a subject preparing for, undergoing organ, tissue or cellular transplantation; or having or expected of developing GvHD for reducing the risk of, preventing or treating rejection or GvHD. In certain embodiments, combination compositions of anti-CD3 immunotoxin and peripheral blood cells from a donor are contemplated.

Abstract: Curative and prophylactic therapies for microvascular and/or macrovascular thrombosis are provided, as are prophylactic therapies capable of preventing fibrinolysis shutdown and therapies for non-thrombotic disorders. Methods provide for administering a therapeutically effective amount of an annexin A2.

Abstract: IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25+ and/or CCR4+ cutaneous T cell lymphoma, and other human CD25+ or CCR4+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25+ or CCR4+ Tregs.

Abstract: Mutant forms of human CTLA4, and their use, e.g., in xenotransplantation.

Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.

Abstract: This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.

Abstract: Anti-human chemokine (C—C motif) Receptor 4 immunotoxins and methods of use thereof, e.g., for depleting Tregs as an immunotherapy for the treatment of cancer; for the treatment of cancers associated with CCR4+ tumor cells such as skin homing cutaneous T cell lymphoma, adult T cell leukemia/lymphoma, and acute T-cell lymphoblastic leukemia; and for the depletion of CCCR4+ Th2 cells for the treatment of allergy-related conditions such as asthma.

Abstract: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.

Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.

Abstract: Mutant forms of human CTLA4, and their use, e.g., in xenotransplantation.

Abstract: This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.

Abstract: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.

Abstract: Non-integrating, Rev-dependent (NIRD) lentiviral vectors and NIRD lentiviral particles carrying a therapeutic gene, such as DT-A or TRAF6 and methods of making the same are disclosed. The intracellular expression of DT-A or TRAF6 results in the selective killing of HIV-positive cells and, thus, these NIRD lentiviral vectors and lentiviral particles can be used in methods to kill HIV-infected cells or treat to HIV-infected subjects. Also disclosed is a human cell line comprising a mutation in the EF2 gene that confers resistance to DT-A.

Abstract: A novel mechanical testing grip is disclosed which accounts for both eccentricity between the load cell and cross head, as well as machining tolerances in the specimen. The device includes a ball and socket joint disposed between two alignment members and secured by connecting members. The connecting members have curved elements for contacting correspondingly curved apertures of the alignment members so that substantially no extra force is exerted upon the test specimen. The grip does not require any heating or excessive waiting periods prior to conducting a mechanical test and can reduce the misalignment of a mechanical test specimen below about 0.02.degree. from the load axis.